Pyxis Oncology's PYX-201 gets Fast Track Designation from FDA for head and neck cancer

From Nasdaq: 2025-02-26 08:35:07

Pyxis Oncology, Inc. announced that their drug candidate PYX-201 received Fast Track Designation from the FDA for treating recurrent or metastatic head and neck squamous cell carcinoma. This designation aims to speed up the review process for drugs targeting serious conditions. PYX-201 is undergoing Phase 1 studies for different solid tumors.



Read more at Nasdaq: Pyxis Oncology Gets Fast Track Designation For PYX-201 In Head And Neck Cancer